ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560 PHASE2 COMPLETED Results posted

To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib in combination with standard adjuvant chemoradiation and chemotherapy in patients with resected adenocarcinoma of the pancreas.

Details

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	PHASE2
Status	COMPLETED
Enrolment	48
Start date	Thu Mar 16 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Feb 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pancreatic Cancer

Interventions

• erlotinib hydrochloride

Countries

United States